Kerry Mullaney
YOU?
Author Swipe
View article: Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 4. Treatments prior to identification of acquired BRAF fusions.
View article: Supplemental Figure 6 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 6 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 6. Oncoprint for acquired BRAF fusions.
View article: Data from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Data from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Purpose:Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course.Experimental Design:We collected data from patients…
View article: Supplemental Figure 5 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 5 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 5. Oncoprint for de novo BRAF fusions (≥10%) for most common histologies.
View article: Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 2. Structures of novel BRAF fusions that had confirmatory RNA-sequencing and transcript IDs.
View article: Supplemental Table 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 2. 5’ fusion gene partners.
View article: Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
View article: Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 4. Oncoprint for de novo BRAF fusions.
View article: Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 4. Oncoprint for de novo BRAF fusions.
View article: Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 1. Baseline characteristics of patients with de novo and acquired BRAF fusions.
View article: Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 1. Consort Diagram.
View article: Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 3: Baseline characteristics of patients with de novo BRAF fusions treated with MAPK-pathway directed therapies.
View article: Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 1. Consort Diagram.
View article: Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 1 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 1. Baseline characteristics of patients with de novo and acquired BRAF fusions.
View article: Supplemental Figure 5 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 5 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 5. Oncoprint for de novo BRAF fusions (≥10%) for most common histologies.
View article: Supplemental Figure 6 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 6 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 6. Oncoprint for acquired BRAF fusions.
View article: Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 3. Structures of top 13 most common BRAF fusion isoforms.
View article: Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 3 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 3. Structures of top 13 most common BRAF fusion isoforms.
View article: Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Figure 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Figure 2. Structures of novel BRAF fusions that had confirmatory RNA-sequencing and transcript IDs.
View article: Data from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Data from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Purpose:Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course.Experimental Design:We collected data from patients…
View article: Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 4 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 4. Treatments prior to identification of acquired BRAF fusions.
View article: Supplemental Table 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Supplemental Table 2 from Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Supplemental Table 2. 5’ fusion gene partners.
View article: Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets
Tumor-Agnostic Genomic and Clinical Analysis of <i>BRAF</i> Fusions Identifies Actionable Targets Open
Purpose: Even though BRAF fusions are increasingly detected in standard multigene next-generation sequencing panels, few reports have explored their structure and impact on clinical course. Experimental Design: We collected data from patie…
View article: Data from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
Data from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors Open
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219…
View article: Supplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
Supplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors Open
List of all gene fusions and associated DNA methylation classes and scores
View article: Supplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
Supplementary Table 2 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors Open
List of all gene fusions and associated DNA methylation classes and scores
View article: Supplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
Supplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors Open
List of genes in the fusion panels
View article: Supplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors
Supplementary Table 1 from Impact of Rare and Multiple Concurrent Gene Fusions on Diagnostic DNA Methylation Classifier in Brain Tumors Open
List of genes in the fusion panels